Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

(2012) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

(2011) K. Takezawa et al.   CLINICAL CANCER RESEARCH

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

The potential for crizotinib in non-small cell lung cancer: a perspective review

(2011) Yung-Jue Bang   Therapeutic Advances in Medical Oncology

Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations

(2010) K. Okamoto et al.   CANCER RESEARCH

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation

(2010) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

(2010) Isamu Okamoto et al.   Therapeutic Advances in Medical Oncology

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

(2009) Isamu Okamoto   FEBS Journal

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer

(2008) Hiroyuki Mano   CANCER SCIENCE

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA